PeptAid is developing a novel peptide-based immunotherapy to treat glioblastoma, the most aggressive and currently incurable brain tumor. Our lead candidate, I49, is a synthetic peptide that targets SPP1, a key driver of immune suppression and tumor progression. By blocking SPP1, I49 reprograms immune cells to fight rather than support the tumor, addressing the root cause of disease. Our goal is to develop a safer, more effective treatment that improves survival and quality of life for patients with this devastating disease.

PeptAid

Org chart

Teams

Offices

PeptAid

Org chart

Teams

Offices

Related companies